A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Finding Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat
Latest Information Update: 10 Apr 2024
At a glance
- Drugs DWJ 211 (Primary)
- Indications Subcutaneous fat disorders
- Focus Therapeutic Use
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 03 Apr 2024 Status changed from active, no longer recruiting to completed.
- 27 Nov 2019 New trial record